Cell growth of tetramer+ and tetramer− CD8+ cells after CD3/IL-2 versus CD3/CD28/IL-2 activation
| Donor no. . | Type of cells . | Tetramer subset . | Cell growth* . | Fold improvement† . | |
|---|---|---|---|---|---|
| CD3/IL-2 . | CD3/CD28 . | ||||
| 2 | Co | Positive | 3.77 | 17.51 | 4.6 |
| Negative | 12.76 | 22.66 | 1.8 | ||
| 3 | Co | Positive | 12.29 | 23.75 | 1.9 |
| Negative | 51.04 | 47.50 | 0.9 | ||
| GMC | Positive | 0.35 | 1.49 | 4.3 | |
| Negative | 4.67 | 1.26 | 0.3 | ||
| 4 | Co | Positive | 8.51 | 32.68 | 3.8 |
| Negative | 179.43 | 151.63 | 0.8 | ||
| GMC | Positive | 0.17 | 1.53 | 8.9 | |
| Negative | 5.67 | 13.13 | 2.3 | ||
| Donor no. . | Type of cells . | Tetramer subset . | Cell growth* . | Fold improvement† . | |
|---|---|---|---|---|---|
| CD3/IL-2 . | CD3/CD28 . | ||||
| 2 | Co | Positive | 3.77 | 17.51 | 4.6 |
| Negative | 12.76 | 22.66 | 1.8 | ||
| 3 | Co | Positive | 12.29 | 23.75 | 1.9 |
| Negative | 51.04 | 47.50 | 0.9 | ||
| GMC | Positive | 0.35 | 1.49 | 4.3 | |
| Negative | 4.67 | 1.26 | 0.3 | ||
| 4 | Co | Positive | 8.51 | 32.68 | 3.8 |
| Negative | 179.43 | 151.63 | 0.8 | ||
| GMC | Positive | 0.17 | 1.53 | 8.9 | |
| Negative | 5.67 | 13.13 | 2.3 | ||
Cell growth was calculated as the ratio of absolute numbers of tetramer+, CD8+ or tetramer−, CD8+ cells in Co cells or GMCs to absolute numbers in the initial PBMC suspension.
Improvement of CD3/CD28/IL-2 over CD3/IL-2 stimulation was calculated as the ratio of cell growth after CD3/CD28/IL-2 activation to the cell growth after CD3/IL-2 activation.